Adefovir combined with hepatitis C virus treatment may prevent hepatitis B reactivation after hepatitis C virus eradication in hepatitis B and C virus carriers.
This observation reports that a hepatitis B virus (HBV) reactivation, as the result of hepatitis C virus (HCV) eradication on a dominant HCV coinfected HBV/HCV patient, was subsequently prevented by treating both viral infections together. This finding raises the question as to whether preemptive HBV treatment should be prescribed along with HCV treatment to prevent HBV from being reactive after HCV eradication in coinfected HBV/HCV patients.
Renou
Christophe
C
Gastroenterology Department, Hyères Hospital, Hyères, France. crenou@ch-hyeres.fr
Cadranel
Jean-François
JF
Pariente
Alexandre
A
Pénaranda
Guillaume
G
Bourlière
Marc
M
Halfon
Philippe
P
Igual
Jean-Pierre
JP
Harafa
Abdelouahid
A
Muller
Pierre
P
Bertrand
Jean-Jacques
JJ
Laugier
René
R
D000225:Adenine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D002353:Carrier State / Q000188:drug therapy / Q000821:virology; D004359:Drug Therapy, Combination; D006509:Hepatitis B / Q000150:complications / Q000188:drug therapy / Q000517:prevention & control*; D006515:Hepatitis B virus / Q000187:drug effects / Q000502:physiology*; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008297:Male; D063065:Organophosphonates / Q000627:therapeutic use*; D014775:Virus Activation / Q000187:drug effects*
D000998:Antiviral Agents; D063065:Organophosphonates; C053001:adefovir; D000225:Adenine